Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Sanofi Says Sarclisa Shows 'Unprecedented Median Progression-Free Survival' In Multiple Myeloma Patients

Sanofi SA SNY FDA Nasdaq
  • Sanofi SA (NASDAQ:SNY) shared the latest results from the Phase 3 IKEMA trial evaluating Sarclisa (isatuximab) in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy.
  • Sarclisa combined with carfilzomib and dexamethasone (Kd) demonstrated a median progression-free survival (mPFS) of 35.7 months, compared to 19.2 months in patients treated with Kd alone. 
  • Following the FDA recommendations on censoring rules, the analysis showed an mPFS of 41.7 months for Sarclisa combination therapy compared to 20.8 months in patients treated with Kd alone.
  • The time to next treatment for patients treated with Sarclisa combination therapy was 44.9 months versus those treated with Kd alone at 25 months.
  • The safety and tolerability of Sarclisa observed in this analysis were consistent with the safety profile of Sarclisa in other clinical trials, with no new safety signals observed. 
  • Price Action: SNY shares are up 0.74% at $52.42 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Bristol Myers' Opdivo+Yervoy Fails To Meet Survival Endpoint In Untreated Urothelial Cancer
Bristol Myers' Opdivo+Yervoy Fails To Meet Survival Endpoint In Untreated Urothelial Cancer
Bristol Myers Squibb & Co's (NYSE:BMY) Phase 3 CheckMate -901 trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) in urothelial carcinoma did not meet the primary endpoint of overall survival (OS) at the final analysis. The trial compared Opdivo + Yervoy to standard-of-care chemotherapy as a first-line treatment for unresectable or metastatic urothelial carcinoma…
Benzinga
Benzinga
Applied Genetic's Vision Loss Gene Therapy Shows Encouraging Safety, Efficacy At Three Months
Applied Genetic's Vision Loss Gene Therapy Shows Encouraging Safety, Efficacy At Three Months
Applied Genetic Technologies Corp (NASDAQ:AGTC) reported three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501 for X-linked retinitis pigmentosa (XLRP), an inherited condition causing progressive vision loss in boys and young men.  AGTC-501 is a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene. There were robust…
Benzinga
Benzinga
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
AVROBIO Inc (NASDAQ:AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells.  Excess cystine damages cells and often forms crystals that can build up and cause many…
Benzinga
Benzinga
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Cyndi Lauper ‘cried’ after song title was made into feminist slogan for protests
Placards reading ‘Girls just want to have fundamental rights’ are often seen at women’s marches.
Evening Standard
Evening Standard
NYC Woman Gets Slammed For “Tone-Deaf” Demand About Airplane Bathrooms
"I also would scream if my mom tried to record me going to the bathroom." The post NYC Woman Gets Slammed For “Tone-Deaf” Demand About Airplane Bathrooms first appeared on Bored Panda.
Bored Panda
Bored Panda
Billions of cherished photos at risk; only a third of Americans back up their precious pics to the cloud
Americans take billions of photos, yet only a small fraction make it into printed albums, risking future loss.
TechRadar
TechRadar
Amazon plots first female 007 as James Bond franchise plans shake-up
Other proposals included spin-offs centred around Bond’s CIA ally Felix Leiter
Evening Standard
Evening Standard
What Amazon MGM’s creative control over the James Bond film franchise means for the future of 007
James Bond was front and center at the 2025 Academy Awards – and in a somewhat curious way.
The Conversation
The Conversation
Mickey 17 Is a Misbegotten Sci-Fi Trump Satire
Robert Pattinson stars as spacefaring multiples in director Bong Joon-ho's disappointing follow-up to Parasite.
Reason
Reason
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
Download on the AppStore Get it on Google Play